Neuronetics Investor Relations Material
Latest events
Q2 2025
Neuronetics
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Neuronetics Inc
Access all reports
Neuronetics Inc develops and markets non-invasive neurostimulation therapies for mental health disorders. The company’s primary product is a transcranial magnetic stimulation system used in the treatment of major depressive disorder and other psychiatric conditions. It serves healthcare providers in the United States. The company is headquartered in Malvern, Pennsylvania, and its shares are listed on the NASDAQ.
Key slides for Neuronetics Inc
Q2 2025
Neuronetics Inc
Q2 2025
Neuronetics Inc
Latest articles
)
Verisure: Security Leader Ready for a Comeback IPO
Verisure, Europe's leading monitored alarm provider, is preparing a comeback IPO in 2025 that could be one of the year's most significant listings.
16 Sep 2025
)
Stephen J. Squeri: American Express Veteran Chairman and CEO
Stephen Squeri has spent over four decades at American Express, rising through the ranks to lead one of the world's most recognized brands.
15 Sep 2025
)
Where to? The Story of Uber
Uber's journey from rule-breaking disruptor to disciplined dual-app giant, now shaping the future of mobility, delivery, and autonomy.
5 Sep 2025
Ticker symbol
STIM
Country
🇺🇸 United States